ATI Stock Recent News

Investors need to pay close attention to ATI stock based on the movements in the options market lately.

DOWNERS GROVE, Ill. , March 4, 2025 /PRNewswire/ -- ATI Physical Therapy, Inc. (OTCMKTS: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, announced today that on March 3, 2025, it closed a $26 million 8% second lien PIK convertible note financing.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DALLAS , Feb. 28, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced that a tentative agreement has been reached with the leadership of the United Steelworkers (USW) on a new six-year Master Contract. This tentative agreement will be presented to the USW general membership for respective ratification votes.

Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Investigational New Drug submission Further strengthened government partnerships, reinforcing Appili's position as a key player in biodefense and infectious disease solutions. HALIFAX, Nova Scotia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2025, which ended on December 31, 2024.

ATI's new additive manufacturing facility includes the industry's largest format and most advanced capabilities.

World-class facility includes industry's largest format, most advanced capabilities MARGATE, Fla. , Feb. 13, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) celebrated the commissioning of its world-class Additive Manufacturing Products facility, bringing on-line the most advanced large-format, metal additive manufacturing capabilities in the industry.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases.

ATI experienced strong demand for specialty materials, driving a 10.2% year-on-year revenue increase to $1.17 billion in Q4 FY24. Continued healthy demand for the company's material primarily in the A&D end market, and backlog levels should fuel top line growth in the short term. Favorable mix and enhanced productivity should result in margin growth in the quarters ahead.